Michael A Jakupec

List of Publications by Citations

Source: https://exaly.com/author-pdf/1410878/michael-a-jakupec-publications-by-citations.pdf
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

190 papers	11,111 citations	55 h-index	100 g-index
196 ext. papers	11,956 ext. citations	4.6 avg, IF	5.96 L-index

#	Paper	IF	Citations
190	From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). *Journal of Inorganic Biochemistry*, **2006**, 100, 891-904	4.2	806
189	Antitumour metal compounds: more than theme and variations. *Dalton Transactions*, **2008**, 183-94	4.3	702
188	KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients. *Chemistry and Biodiversity*, **2008**, 5, 2140-55	2.5	624
187	Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. *Current Medicinal Chemistry*, **2005**, 12, 2075-94	4.3	565
186	NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. *Chemical Science*, **2014**, 5, 2925-2932	9.4	456
185	Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity. *Journal of Medicinal Chemistry*, **2007**, 50, 2185-93	8.3	191
184	Resistance against novel anticancer metal compounds: differences and similarities. *Drug Resistance Updates*, **2008**, 11, 1-16	23.2	183
183	Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. *Dalton Transactions*, **2006**, 1796-802	4.3	174
182	Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy. *Journal of Analytical Atomic Spectrometry*, **2004**, 19, 46	3.7	174
181	Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Ruthenium-Arene Compounds. *Organometallics*, **2008**, 27, 2405-2407	3.8	171
180	Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. *Journal of Medicinal Chemistry*, **2009**, 52, 916-25	8.3	156
179	Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential. *Journal of Medicinal Chemistry*, **2005**, 48, 2831-7	8.3	145
178	Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation. *Journal of Medicinal Chemistry*, **2009**, 52, 5032-43	8.3	133
177	Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase. *Journal of Medicinal Chemistry*, **2007**, 50, 1254-65	8.3	129
176	Gallium in cancer treatment. *Current Topics in Medicinal Chemistry*, **2004**, 4, 1575-83	3	126
175	Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder. *Chemical Communications*, **2012**, 48, 4839-41	5.8	125
174	Highly Antiproliferative Ruthenium(II) and Osmium(II) Arene Complexes with Paullone-Derived Ligands. *Organometallics*, **2007**, 26, 6643-6652	3.8	123

173	Structure-activity relationships of targeted RuII(η6-p-cymene) anticancer complexes with flavonol-derived ligands. *Journal of Medicinal Chemistry*, **2012**, 55, 10512-22	8.3	119
172	Organometallic anticancer complexes of lapachol: metal centre-dependent formation of reactive oxygen species and correlation with cytotoxicity. *Chemical Communications*, **2013**, 49, 3348-50	5.8	116
171	Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). *Biochemical Pharmacology*, **2006**, 71, 426-40	6	114
170	Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action. *Chemical Science*, **2015**, 6, 2449-2456	9.4	105
169	Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro. *Chemistry - A European Journal*, **2009**, 15, 12283-91	4.8	102
168	Physicochemical Studies and Anticancer Potency of Ruthenium η6-Cymene Complexes Containing Antibacterial Quinolones. *Organometallics*, **2011**, 30, 2506-2512	3.8	101
167	In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands. *Chemistry - A European Journal*, **2008**, 14, 9046-57	4.8	100
166	The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. *Cancer Letters*, **2005**, 226, 115-21	9.9	100
165	Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter?. *Inorganic Chemistry*, **2010**, 49, 7953-63	5.1	98
164	Novel metal(II) arene 2-pyridinecarbothioamides: a rationale to orally active organometallic anticancer agents. *Chemical Science*, **2013**, 4, 1837	9.4	95
163	Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes. *Journal of Inorganic Biochemistry*, **2011**, 105, 46-51	4.2	94
162	Synthesis, structure, spectroscopic and in vitro antitumour studies of a novel gallium(III) complex with 2-acetylpyridine (4)N-dimethylthiosemicarbazone. *Journal of Inorganic Biochemistry*, **2002**, 91, 298-305	4.2	91
161	Synthesis, X-ray diffraction structures, spectroscopic properties, and in vitro antitumor activity of isomeric (1H-1,2,4-triazole)Ru(III) complexes. *Inorganic Chemistry*, **2003**, 42, 6024-31	5.1	91
160	Influence of the Arene Ligand, the Number and Type of Metal Centers, and the Leaving Group on the in Vitro Antitumor Activity of Polynuclear Organometallic Compounds. *Organometallics*, **2009**, 28, 6260-6265	3.8	90
159	Preclinical characterization of anticancer gallium(III) complexes: solubility, stability, lipophilicity and binding to serum proteins. *Journal of Inorganic Biochemistry*, **2006**, 100, 1819-26	4.2	90
158	Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. *Journal of Analytical Atomic Spectrometry*, **2009**, 24, 51-61	3.7	88
157	A SAR study of novel antiproliferative ruthenium and osmium complexes with quinoxalinone ligands in human cancer cell lines. *Journal of Medicinal Chemistry*, **2012**, 55, 3398-413	8.3	87
156	Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules. *Chemical Communications*, **2012**, 48, 1475-7	5.8	82

155	Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences. *Dalton Transactions*, **2010**, 39, 7345-52	4.3	81
154	Metal-based paullones as putative CDK inhibitors for antitumor chemotherapy. *Journal of Medicinal Chemistry*, **2007**, 50, 6343-55	8.3	80
153	Novel di- and tetracarboxylatoplatinum(IV) complexes. Synthesis, characterization, cytotoxic activity, and DNA platination. *Journal of Medicinal Chemistry*, **2007**, 50, 6692-9	8.3	79
152	From Pyrone to Thiopyrone Ligands Rendering Maltol-Derived Ruthenium(II) Arene Complexes That Are Anticancer Active in Vitro. *Organometallics*, **2009**, 28, 4249-4251	3.8	78
151	Fluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex. *Dalton Transactions*, **2010**, 39, 704-6	4.3	72
150	An Organoruthenium Anticancer Agent Shows Unexpected Target Selectivity For Plectin. *Angewandte Chemie - International Edition*, **2017**, 56, 8267-8271	16.4	71
149	NanoSIMS combined with fluorescence microscopy as a tool for subcellular imaging of isotopically labeled platinum-based anticancer drugs. *Chemical Science*, **2014**, 5, 3135	9.4	71
148	3-Hydroxyflavones vs. 3-hydroxyquinolinones: structure-activity relationships and stability studies on Ru(II)(arene) anticancer complexes with biologically active ligands. *Dalton Transactions*, **2013**, 42, 6193-202	4.3	71
147	Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines. *Investigational New Drugs*, **2016**, 34, 261-8	4.3	70
146	Theoretical investigations and density functional theory based quantitative structure-activity relationships model for novel cytotoxic platinum(IV) complexes. *Journal of Medicinal Chemistry*, **2013**, 56, 330-44	8.3	69
145	Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs. *Dalton Transactions*, **2012**, 41, 14404-15	4.3	68
144	Antitumor pentamethylcyclopentadienyl rhodium complexes of maltol and allomaltol: synthesis, solution speciation and bioactivity. *Journal of Inorganic Biochemistry*, **2014**, 134, 57-65	4.2	64
143	Water-Soluble Mixed-Ligand Ruthenium(II) and Osmium(II) Arene Complexes with High Antiproliferative Activity. *Organometallics*, **2008**, 27, 6587-6595	3.8	64
142	From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands. *Journal of Inorganic Biochemistry*, **2011**, 105, 224-31	4.2	63
141	Effect of metal ion complexation and chalcogen donor identity on the antiproliferative activity of 2-acetylpyridine N,N-dimethyl(chalcogen)semicarbazones. *Journal of Inorganic Biochemistry*, **2007**, 101, 1946-57	4.2	62
140	Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin. *European Journal of Medicinal Chemistry*, **2011**, 46, 5456-64	6.8	59
139	L- and D-proline thiosemicarbazone conjugates: coordination behavior in solution and the effect of copper(II) coordination on their antiproliferative activity. *Inorganic Chemistry*, **2012**, 51, 9309-21	5.1	58
138	Tuning the anticancer activity of maltol-derived ruthenium complexes by derivatization of the 3-hydroxy-4-pyrone moiety. *Journal of Organometallic Chemistry*, **2009**, 694, 922-929	2.3	58

137	Solid-phase synthesis of oxaliplatin-TAT peptide bioconjugates. *Dalton Transactions*, **2012**, 41, 3001-5	4.3	57
136	First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro. *Metallomics*, **2019**, 11, 1044-1048	4.5	56
135	Osmium NAMI-A analogues: synthesis, structural and spectroscopic characterization, and antiproliferative properties. *Inorganic Chemistry*, **2007**, 46, 5023-33	5.1	55
134	Metal-Arene Complexes with Indolo[3,2-c]-quinolines: Effects of Ruthenium vs Osmium and Modifications of the Lactam Unit on Intermolecular Interactions, Anticancer Activity, Cell Cycle, and Cellular Accumulation. *Organometallics*, **2013**, 32, 903-914	3.8	54
133	Ruthenium- and Osmium-Arene Complexes of 2-Substituted Indolo[3,2-c]quinolines: Synthesis, Structure, Spectroscopic Properties, and Antiproliferative Activity. *Organometallics*, **2011**, 30, 273-283	3.8	53
132	Biological activity of ruthenium and osmium arene complexes with modified paullones in human cancer cells. *Journal of Inorganic Biochemistry*, **2012**, 116, 180-7	4.2	52
131	Conjugation of organoruthenium(II) 3-(1H-benzimidazol-2-yl)pyrazolo[3,4-b]pyridines and indolo[3,2-d]benzazepines to recombinant human serum albumin: a strategy to enhance cytotoxicity in cancer cells. *Inorganic Chemistry*, **2011**, 50, 12669-79	5.1	51
130	Synthesis and biological studies of some gold(I) complexes containing functionalised alkynes. *Dalton Transactions*, **2009**, 10841-5	4.3	51
129	Synthesis, characterization, and in vitro antitumor activity of osteotropic diam(m)ineplatinum(II) complexes bearing a N,N-bis(phosphonomethyl)glycine ligand. *Journal of Medicinal Chemistry*, **2003**, 46, 4946-51	8.3	51
128	Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds. *Journal of Biological Inorganic Chemistry*, **2012**, 17, 465-74	3.7	49
127	Structure-activity relationships of highly cytotoxic copper(II) complexes with modified indolo[3,2-c]quinoline ligands. *Inorganic Chemistry*, **2010**, 49, 11084-95	5.1	49
126	Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate. *Chemistry - A European Journal*, **2013**, 19, 9297-307	4.8	48
125	Reversion of structure-activity relationships of antitumor platinum complexes by acetoxime but not hydroxylamine ligands. *Molecular Pharmacology*, **2007**, 71, 357-65	4.3	48
124	A glucose derivative as natural alternative to the cyclohexane-1,2-diamine ligand in the anticancer drug oxaliplatin?. *ChemMedChem*, **2007**, 2, 505-14	3.7	47
123	X-ray absorption near edge structure spectroscopy to resolve the in vivo chemistry of the redox-active indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019). *Journal of Medicinal Chemistry*, **2013**, 56, 1182-96	8.3	46
122	Novel cis- and trans-configured bis(oxime)platinum(II) complexes: synthesis, characterization, and cytotoxic activity. *Inorganic Chemistry*, **2010**, 49, 5669-78	5.1	46
121	New platinum-oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro. *Journal of Inorganic Biochemistry*, **2010**, 104, 799-814	4.2	46
120	Synthesis, crystal structure and cytotoxicity of new oxaliplatin analogues indicating that improvement of anticancer activity is still possible. *European Journal of Medicinal Chemistry*, **2004**, 39, 707-14	6.8	46

119	Organometallic indolo[3,2-c]quinolines versus indolo[3,2-d]benzazepines: synthesis, structural and spectroscopic characterization, and biological efficacy. *Journal of Biological Inorganic Chemistry*, **2010**, 15, 903-18	3.7	45
118	Synthesis, crystal structure and pH dependent cytotoxicity of (SP-4-2)-bis(2-aminoethanolato-2N,O)platinum(II) a representative of novel pH sensitive anticancer platinum complexes. *Inorganica Chimica Acta*, **2004**, 357, 3237-3244	2.7	45
117	{(1R,2R,4R)-4-methyl-1,2-cyclohexanediamine}oxalatoplatinum(II): a novel enantiomerically pure oxaliplatin derivative showing improved anticancer activity in vivo. *Journal of Medicinal Chemistry*, **2010**, 53, 7356-64	8.3	43
116	Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates. *Inorganic Chemistry*, **2017**, 56, 528-541	5.1	42
115	En route to osmium analogues of KP1019: synthesis, structure, spectroscopic properties and antiproliferative activity of trans-[Os(IV)Cl4(Hazole)2]. *Inorganic Chemistry*, **2011**, 50, 7690-7	5.1	42
114	Highly cytotoxic copper(II) complexes with modified paullone ligands. *Inorganic Chemistry*, **2010**, 49, 302-11	5.1	41
113	Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models. *Metallomics*, **2017**, 9, 309-322	4.5	40
112	The first metal-based paullone derivative with high antiproliferative activity in vitro. *Inorganic Chemistry*, **2006**, 45, 1945-50	5.1	40
111	Gallium and Other Main Group Metal Compounds as Antitumor Agents **2004**, 425-462		40
110	A novel class of bis- and tris-chelate diam(m)inebis(dicarboxylato)platinum(IV) complexes as potential anticancer prodrugs. *Journal of Medicinal Chemistry*, **2014**, 57, 6751-64	8.3	39
109	Ruthenium- and osmium-arene-based paullones bearing a TEMPO free-radical unit as potential anticancer drugs. *Chemical Communications*, **2012**, 48, 8559-61	5.8	39
108	Anticancer activity of methyl-substituted oxaliplatin analogs. *Molecular Pharmacology*, **2012**, 81, 719-28	4.3	39
107	Ruthenium and Other Non-Platinum Anticancer Compounds **2011**, 151-174		39
106	Novel bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) complexes with exceptionally high cytotoxicity. *Journal of Inorganic Biochemistry*, **2008**, 102, 2072-7	4.2	39
105	The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines. *Melanoma Research*, **2009**, 19, 283-93	3.3	38
104	Towards targeting anticancer drugs: ruthenium(ii)-arene complexes with biologically active naphthoquinone-derived ligand systems. *Dalton Transactions*, **2016**, 45, 13091-103	4.3	38
103	Ruthenium(II) Complexes of Thiosemicarbazones: The First Water-Soluble Complex with pH-Dependent Antiproliferative Activity. *European Journal of Inorganic Chemistry*, **2007**, 2007, 2870-2878	2.3	37
102	Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs. *Investigational New Drugs*, **2015**, 33, 835-47	4.3	36

101	The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs. *Journal of Inorganic Biochemistry*, **2016**, 160, 264-74	4.2	36
100	LA-ICP-MS imaging in multicellular tumor spheroids - a novel tool in the preclinical development of metal-based anticancer drugs. *Metallomics*, **2016**, 8, 398-402	4.5	36
99	Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles. *Inorganic Chemistry*, **2013**, 52, 6273-85	5.1	36
98	The first ruthenium-based paullones: syntheses, X-ray diffraction structures, and spectroscopic and antiproliferative properties in vitro. *Inorganic Chemistry*, **2007**, 46, 3645-56	5.1	36
97	Novel endothall-containing platinum(IV) complexes: synthesis, characterization, and cytotoxic activity. *Chemistry and Biodiversity*, **2008**, 5, 2160-70	2.5	34
96	Behavior of platinum(iv) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation. *Metallomics*, **2016**, 8, 422-33	4.5	32
95	Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity. *Journal of Medicinal Chemistry*, **2012**, 55, 11052-61	8.3	32
94	Influence of reducing agents on the cytotoxic activity of platinum(IV) complexes: induction of G2/M arrest, apoptosis and oxidative stress in A2780 and cisplatin resistant A2780cis cell lines. *Metallomics*, **2015**, 7, 1078-90	4.5	31
93	Mono-carboxylated diaminedichloridoplatinum(IV) complexes--selective synthesis, characterization, and cytotoxicity. *Dalton Transactions*, **2011**, 40, 8187-92	4.3	31
92	Triapine and a more potent dimethyl derivative induce endoplasmic reticulum stress in cancer cells. *Molecular Pharmacology*, **2014**, 85, 451-9	4.3	30
91	Synthesis, characterization, and cytotoxic activity of novel potentially pH-sensitive nonclassical platinum(II) complexes featuring 1,3-dihydroxyacetone oxime ligands. *Inorganic Chemistry*, **2011**, 50, 10673-81	5.1	30
90	Influence of the Arene Ligand and the Leaving Group on the Anticancer Activity of (Thio)maltol Ruthenium(II)(η6-Arene) Complexes. *Australian Journal of Chemistry*, **2010**, 63, 1521	1.2	30
89	Ruthenium-nitrosyl complexes with glycine, L-alanine, L-valine, L-proline, D-proline, L-serine, L-threonine, and L-tyrosine: synthesis, X-ray diffraction structures, spectroscopic and electrochemical properties, and antiproliferative activity. *Inorganic Chemistry*, **2014**, 53, 2718-29	5.1	29
88	Osmium(IV) complexes with 1H- and 2H-indazoles: tautomer identity versus spectroscopic properties and antiproliferative activity. *Journal of Inorganic Biochemistry*, **2012**, 113, 47-54	4.2	29
87	X-ray absorption spectroscopy of an investigational anticancer gallium(III) drug: interaction with serum proteins, elemental distribution pattern, and coordination of the compound in tissue. *Journal of Medicinal Chemistry*, **2012**, 55, 5601-13	8.3	29
86	Am(m)ines make the difference: organoruthenium am(m)ine complexes and their chemistry in anticancer drug development. *Chemistry - A European Journal*, **2013**, 19, 4308-18	4.8	29
85	Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action. *Inorganic Chemistry*, **2018**, 57, 2851-2864	5.1	28
84	Guanidine platinum(II) complexes: synthesis, in vitro antitumor activity, and DNA interactions. *Journal of Inorganic Biochemistry*, **2014**, 133, 33-9	4.2	28

83	Bulky N(,N)-(di)alkylethane-1,2-diamineplatinum(II) compounds as precursors for generating unsymmetrically substituted platinum(IV) complexes. *Inorganic Chemistry*, **2013**, 52, 8151-62	5.1	28
82	Synthesis, structures and in vitro cytotoxicity of some platinum(II) complexes containing thiocarbamate esters. *Journal of Inorganic Biochemistry*, **2008**, 102, 2067-71	4.2	28
81	Novel glucose-ferrocenyl derivatives: synthesis and properties. *New Journal of Chemistry*, **2002**, 26, 671-673	3.3	28
80	Synthesis, X-ray diffraction structure, spectroscopic properties and antiproliferative activity of a novel ruthenium complex with constitutional similarity to cisplatin. *Dalton Transactions*, **2009**, 3334-9	4.3	27
79	Synthesis, structure, spectroscopic properties, and antiproliferative activity in vitro of novel osmium(III) complexes with azole heterocycles. *Inorganic Chemistry*, **2008**, 47, 7338-47	5.1	27
78	Organometallic 3-(1H-benzimidazol-2-yl)-1H-pyrazolo[3,4-b]pyridines as potential anticancer agents. *Inorganic Chemistry*, **2011**, 50, 11715-28	5.1	26
77	Thiomaltol-Based Organometallic Complexes with 1-Methylimidazole as Leaving Group: Synthesis, Stability, and Biological Behavior. *Chemistry - A European Journal*, **2016**, 22, 17269-17281	4.8	25
76	Synthesis and in vivo anticancer evaluation of poly(organo)phosphazene-based metallodrug conjugates. *Dalton Transactions*, **2017**, 46, 12114-12124	4.3	25
75	{Ru(CO)}-Core complexes with benzimidazole ligands: synthesis, X-ray structure and evaluation of anticancer activity in vivo. *Dalton Transactions*, **2017**, 46, 3025-3040	4.3	23
74	Impact of the equatorial coordination sphere on the rate of reduction, lipophilicity and cytotoxic activity of platinum(IV) complexes. *Journal of Inorganic Biochemistry*, **2017**, 174, 119-129	4.2	22
73	1,3-Dioxoindan-2-carboxamides as Bioactive Ligand Scaffolds for the Development of Novel Organometallic Anticancer Drugs. *Organometallics*, **2015**, 34, 848-857	3.8	22
72	Solution equilibria and antitumor activities of pentamethylcyclopentadienyl rhodium complexes of picolinic acid and deferiprone. *Journal of Coordination Chemistry*, **2015**, 68, 1583-1601	1.6	20
71	Biological properties of novel ruthenium- and osmium-nitrosyl complexes with azole heterocycles. *Journal of Biological Inorganic Chemistry*, **2016**, 21, 347-56	3.7	20
70	Ruthenium- and osmium-arene complexes of 8-substituted indolo[3,2-]quinolines: Synthesis, X-ray diffraction structures, spectroscopic properties, and antiproliferative activity. *Inorganica Chimica Acta*, **2012**, 393, 252-260	2.7	20
69	Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019. *Journal of Biological Inorganic Chemistry*, **2011**, 16, 1205-15	3.7	20
68	[Os(IV)Cl(5)(Hazole)](-) complexes: synthesis, structure, spectroscopic properties, and antiproliferative activity. *Inorganic Chemistry*, **2009**, 48, 10737-47	5.1	20
67	Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups - A rational approach toward exploiting the platinum(IV) prodrug strategy. *Journal of Inorganic Biochemistry*, **2015**, 153, 259-271	4.2	19
66	Flavonoid-Based Organometallics with Different Metal Centers Investigations of the Effects on Reactivity and Cytotoxicity. *European Journal of Inorganic Chemistry*, **2016**, 2016, 240-246	2.3	19

65	Platinum(IV) Complexes Featuring One or Two Axial Ferrocene Bearing Ligands Synthesis, Characterization, and Cytotoxicity. *European Journal of Inorganic Chemistry*, **2014**, 2014, 484-492	2.3	19
64	{Ru(CO)x}-core complexes with selected azoles: Synthesis, X-ray structure, spectroscopy, DFT analysis and evaluation of cytotoxic activity against human cancer cells. *Polyhedron*, **2014**, 81, 227-237	2.7	18
63	Dicopper(II) and dizinc(II) complexes with nonsymmetric dinucleating ligands based on indolo[3,2-c]quinolines: synthesis, structure, cytotoxicity, and intracellular distribution. *Inorganic Chemistry*, **2013**, 52, 10137-46	5.1	18
62	Novel oximato-bridged platinum(II) di- and trimer(s): synthetic, structural, and in vitro anticancer activity studies. *Inorganic Chemistry*, **2012**, 51, 7153-63	5.1	17
61	N- and S-donor leaving groups in triazole-based ruthena(ii)cycles: potent anticancer activity, selective activation, and mode of action studies. *Dalton Transactions*, **2018**, 47, 4625-4638	4.3	16
60	Influence of the coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes. *Frontiers in Chemistry*, **2013**, 1, 27	5	16
59	Cytotoxicity and preliminary mode of action studies of novel 2-aryl-4-thiopyrone-based organometallics. *Dalton Transactions*, **2016**, 45, 724-33	4.3	15
58	A highly cytotoxic modified paullone ligand bearing a TEMPO free-radical unit and its copper(II) complex as potential hR2 RNR inhibitors. *Chemical Communications*, **2013**, 49, 10007-9	5.8	15
57	Low-Generation Polyamidoamine Dendrimers as Drug Carriers for Platinum(IV) Complexes. *European Journal of Inorganic Chemistry*, **2017**, 2017, 1713-1720	2.3	15
56	Influence of extracellular pH on the cytotoxicity, cellular accumulation, and DNA interaction of novel pH-sensitive 2-aminoalcoholatoplatinum(II) complexes. *Journal of Biological Inorganic Chemistry*, **2013**, 18, 249-60	3.7	14
55	Synthesis, Cytotoxicity, and Structure-Activity Relationships of New Oxaliplatin Derivatives. *Monatshefte Für Chemie*, **2005**, 136, 693-700	1.4	14
54	Post-digestion stabilization of osmium enables quantification by ICP-MS in cell culture and tissue. *Analyst, The*, **2017**, 142, 2327-2332	5	13
53	Complexes of N-hydroxyethyl-N-benzimidazolylmethylethylenediaminediacetic acid with group 12 metals and vanadium-Synthesis, structure and bioactivity of the vanadium complex. *Journal of Inorganic Biochemistry*, **2015**, 147, 147-52	4.2	13
52	Organometallic complexes of (thio)allomaltol-based Mannich-products: Synthesis, stability and preliminary biological investigations. *Journal of Organometallic Chemistry*, **2015**, 782, 69-76	2.3	13
51	The influence of electroporation on cytotoxicity of anticancer ruthenium(III) complex KP1339 in vitro and in vivo. *Anticancer Research*, **2010**, 30, 2055-63	2.3	13
50	Functionalization of Ruthenium(II)(p-cymene)(3-hydroxy-2-pyridone) Complexes with (Thio)Morpholine: Synthesis and Bioanalytical Studies. *ChemPlusChem*, **2017**, 82, 841-847	2.8	12
49	Expanding on the Structural Diversity of Flavone- Derived RutheniumII(6-arene) Anticancer Agents **2015**, 1,		12
48	A novel cytotoxic cerium complex: aquatrichloridobis(1,10-phenanthroline)cerium(III) (KP776). Synthesis, characterization, behavior in H2O, binding towards biomolecules, and antiproliferative activity. *Chemistry and Biodiversity*, **2009**, 6, 2153-65	2.5	12

47	Platinum(IV) Complexes Featuring Axial Michael Acceptor Ligands: Synthesis, Characterization, and Cytotoxicity. *European Journal of Inorganic Chemistry*, **2017**, 2017, 4049-4054	2.3	11
46	Antiproliferative Copper(II) and Platinum(II) Complexes with Bidentate N,N-Donor Ligands. *European Journal of Inorganic Chemistry*, **2017**, 2017, 3115-3124	2.3	11
45	Ein Organoruthenium-Tumortherapeutikum mit unerwartet hoher Selektivität für Plectin. *Angewandte Chemie*, **2017**, 129, 8379-8383	3.6	11
44	Hydrolysis and cytotoxic properties of osmium(II)/(III)-DMSO-azole complexes. Short communication. *Chemistry and Biodiversity*, **2008**, 5, 1588-93	2.5	11
43	Gallium and other main group metal compounds as antitumor agents. *Metal Ions in Biological Systems*, **2004**, 42, 425-62		11
42	Tetra-(-tolyl)antimony(III)-Containing Heteropolytungstates, [{(-tolyl)Sb}(-XWO)] (X = P, As, or Ge): Synthesis, Structure, and Study of Antibacterial and Antitumor Activity. *Inorganic Chemistry*, **2020**, 59, 2978-2987	5.1	10
41	Diamminetetrakis(carboxylato)platinum(IV) complexes--synthesis, characterization, and cytotoxicity. *Chemistry and Biodiversity*, **2012**, 9, 1840-8	2.5	10
40	Synthesis, structures and in vitro cytotoxicity of some cationic cis-platinum(II) complexes containing chelating thiocarbamates. *Journal of Inorganic Biochemistry*, **2011**, 105, 462-6	4.2	10
39	Comparative equilibrium and structural studies of new pentamethylcyclopentadienyl rhodium complexes bearing (O,N) donor bidentate ligands. *Journal of Organometallic Chemistry*, **2017**, 846, 287-295	2.3	9
38	Amidoxime platinum(II) complexes: pH-dependent highly selective generation and cytotoxic activity. *New Journal of Chemistry*, **2017**, 41, 6840-6848	3.6	8
37	Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics. *Metallomics*, **2019**, 11, 1716-1728	4.5	8
36	The rearrangement of tosylated flavones to 1?-(alkylamino)aurones with primary amines. *Tetrahedron*, **2015**, 71, 8953-8959	2.4	8
35	Biological evaluation of novel thiomaltol-based organometallic complexes as topoisomerase II inhibitors. *Journal of Biological Inorganic Chemistry*, **2020**, 25, 451-465	3.7	8
34	Synthesis, Modification, and Biological Evaluation of a Library of Novel Water-Soluble Thiopyridone-Based Organometallic Complexes and Their Unexpected (Biological) Behavior. *Chemistry - A European Journal*, **2020**, 26, 5419-5433	4.8	8
33	Plecstatin-1 induces an immunogenic cell death signature in colorectal tumour spheroids. *Metallomics*, **2020**, 12, 2121-2133	4.5	8
32	Introducing -, -, and -donor leaving groups: an investigation of the chemical and biological properties of ruthenium, rhodium and iridium thiopyridone piano stool complexes. *Dalton Transactions*, **2020**, 49, 15693-15711	4.3	7
31	Aqueous chemistry and antiproliferative activity of a pyrone-based phosphoramidate Ru(arene) anticancer agent. *Dalton Transactions*, **2014**, 43, 9851-5	4.3	7
30	Osmium-Nitrosyl Complexes with Glycine, Picolinic Acid, L-Proline and D-Proline: Synthesis, Structures and Antiproliferative Activity. *Zeitschrift Fur Anorganische Und Allgemeine Chemie*, **2013**, 639, 1590-1597	1.3	7

29	The Effect of Cytoprotective Agents in Platinum Anticancer Therapy **2004**, 179-208		7
28	Single Spheroid Metabolomics: Optimizing Sample Preparation of Three-Dimensional Multicellular Tumor Spheroids. *Metabolites*, **2019**, 9,	5.6	7
27	Bis- and Tetrakis(carboxylato)platinum(IV) complexes with mixed axial ligands - synthesis, characterization, and cytotoxicity. *Chemistry and Biodiversity*, **2015**, 12, 559-74	2.5	6
26	Synthesis and in vitro antitumor potency of (cyclohexane-1,2-diamine)platinum(II) complexes with aminotris(methylenephosphonic acid) as bone-seeking ligand. *Bioinorganic Chemistry and Applications*, **2005**, 3, 179-90	4.2	6
25	Novel phthiocol-based organometallics with tridentate coordination motif and their unexpected cytotoxic behaviour. *Dalton Transactions*, **2020**, 49, 1393-1397	4.3	5
24	Fine-Tuning the Activation Mode of an 1,3-Indandione-Based Ruthenium(II)-Cymene Half-Sandwich Complex by Variation of Its Leaving Group. *Molecules*, **2019**, 24,	4.8	5
23	First insights into the novel class of organometallic compounds bearing a bidentate selenopyridone coordination motif: Synthesis, characterization, stability and biological investigations. *Inorganica Chimica Acta*, **2020**, 513, 119919	2.7	5
22	Heart-cut 2DSEC-RP-LC-ICP-MS as a screening tool in metal-based anticancer research. *Journal of Analytical Atomic Spectrometry*, **2019**, 34, 1279-1286	3.7	4
21	Bis- and Tris(carboxylato)platinum(IV) Complexes with Mixed Am(m)ine Ligands in the trans Position Exhibiting Exceptionally High Cytotoxicity. *European Journal of Inorganic Chemistry*, **2015**, 2015, 1700-1708	2.3	4
20	Water-soluble cationic derivatives of indirubin, the active anticancer component from Indigo naturalis. *Chemistry and Biodiversity*, **2012**, 9, 2175-85	2.5	4
19	Investigations on the Anticancer Potential of Benzothiazole-Based Metallacycles. *Frontiers in Chemistry*, **2020**, 8, 209	5	3
18	Naphthoquinones of natural origin: Aqueous chemistry and coordination to half-sandwich organometallic cations. *Journal of Organometallic Chemistry*, **2020**, 907, 121070	2.3	3
17	Morpho-metabotyping the oxidative stress response. *Scientific Reports*, **2021**, 11, 15471	4.9	3
16	The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo-A Comparison of O,O-, S,O-, and N,N-Chelate Effects. *Chemistry - A European Journal*, **2020**, 26, 2211-2221	4.8	3
15	Synthesis, Characterization, Cytotoxicity, and Time-Dependent NMR Spectroscopic Studies of (SP-4-3)-Oxalato[(1R,2R,4R/1S,2S,4S)-(4-trifluoromethyl-cyclohexane-1,2-diamine)]platinum(II). *European Journal of Inorganic Chemistry*, **2019**, 2019, 856-864	2.3	2
14	Synthesis, characterization, cytotoxic activity, and 19F NMR spectroscopic investigations of (OC-6-33)-diacetato(ethane-1,2-diamine)bis(3,3,3-trifluoropropanoato)platinum(IV) and its platinum(II) counterpart. *Inorganica Chimica Acta*, **2019**, 490, 190-199	2.7	2
13	Design, synthesis, nuclear localization, and biological activity of a fluorescent duocarmycin analog, HxTfA. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 1342-1347	2.9	2
12	Trends and Perspectives of Ruthenium Anticancer Compounds (Non-PDT) **2017**, 271-291		2

11	Tridentate 3-Substituted Naphthoquinone Ruthenium Arene Complexes: Synthesis, Characterization, Aqueous Behavior, and Theoretical and Biological Studies. *Inorganic Chemistry*, **2021**, 60, 9805-9819	5.1	2
10	Nano-scale imaging of dual stable isotope labeled oxaliplatin in human colon cancer cells reveals the nucleolus as a putative node for therapeutic effect. *Nanoscale Advances*, **2021**, 3, 249-262	5.1	2
9	Highly Aromatic Flavan-3-ol Derivatives from Palaeotropical Buch.-Ham Possess Radical Scavenging and Antiproliferative Properties. *Molecules*, **2021**, 26,	4.8	2
8	The Impact of Leaving Group Variation on the Anticancer Activity of Molybdenocenes. *Organometallics*, **2018**, 37, 3909-3916	3.8	2
7	The effect of cytoprotective agents in platinum anticancer therapy. *Metal Ions in Biological Systems*, **2004**, 42, 179-208		2
6	Systematic Study on the Cytotoxic Potency of Commonly Used Dimeric Metal Precursors in Human Cancer Cell Lines.. *ChemistryOpen*, **2022**, e202200019	2.3	2
5	Synthesis, characterization, lipophilicity and cytotoxic properties of novel bis(carboxylato)oxalatobis(1-propylamine)platinum(IV) complexes. *Inorganica Chimica Acta*, **2019**, 491, 76-83	2.7	1
4	Multifunctional Pt(iv) prodrug candidates featuring the carboplatin core and deferoxamine. *Dalton Transactions*, **2021**, 50, 8167-8178	4.3	1
3	Innenr□ktitelbild: Ein Organoruthenium-Tumortherapeutikum mit unerwartet hoher Selektivit□ f□ Plectin (Angew. Chem. 28/2017). *Angewandte Chemie*, **2017**, 129, 8415-8415	3.6	
2	KP772 overcomes multiple drug resistance in malignant lymphoma and leukemia cells in vitro by inducing Bcl-2-independent apoptosis and upregulation of Harakiri. *Journal of Biological Inorganic Chemistry*, **2021**, 26, 897-907	3.7	
1	Water-soluble trithiolato-bridged dinuclear ruthenium(II) and osmium(II) arene complexes with bisphosphonate functionalized ligands as anticancer organometallics. *Journal of Inorganic Biochemistry*, **2021**, 225, 111618	4.2	